Long-term efficacy and safety of paliperidone palmitate monthly injection and oral paliperidone extended-release tablets in schizophrenia, a randomized controlled trial
Acta Psychologica · 2026
DOI: 10.1016/j.actpsy.2025.106087 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Acta Psychologica, 2026. Verfasst von Chunhui Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Xinshi Hospital, Gaoming District, Foshan, Guangdong, China. Hauptthemen laut MEDLINE: Paliperidone Palmitate, Schizophrenia, Antipsychotic Agents. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Foshan Municipal Science and Technology Bureau.
Abstract (Originalsprache)
This study aimed to compare the 9-month efficacy and safety of paliperidone palmitate 1-monthly injection (PP1M) versus oral paliperidone extended-release (ER) tablets in patients with stable schizophrenia (SCZ). A single-center randomized controlled trial was conducted, enrolling 119 adult outpatients (mean age 46.03 years) diagnosed with SCZ (DSM-5 criteria), randomized to PP1M (n = 60) or ER (n = 59). The primary outcome was change in Positive and Negative Syndrome Scale (PANSS) total score, with secondary outcomes including Clinical Global Impression-Severity (CGIS) and Treatment Emergent Symptom Scale (TESS) scores. No statistically significant differences in PANSS total score improvements were observed between groups at 3, 6, and 9 months (P > 0.05). PP1M demonstrated transient superiority in CGI-S reduction at 3 and 6 months (mean difference: -0.31 and - 0.45, respectively; P < 0.05), but this difference dissipated by month 9. No significant differences in tolerability, as measured by TESS scores, were found between groups, with no significant differences in adverse events across follow-up periods. PP1M showed numerically greater (though nonsignificant) improvements in negative symptoms, suggesting potential subtle benefits. In conclusion, this study did not detect significant differences in long-term efficacy or safety between PP1M and ER in stable SCZ patients. While PP1M provided early CGI-S advantages likely attributable to adherence optimization, no inherent pharmacodynamic superiority was observed. These findings support PP1M as a pragmatic option for adherence-challenged patients, emphasizing individualized treatment selection based on preferences and feasibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Xinshi Hospital, Gaoming District, Foshan, Guangdong, China.
- Department of Psychiatry, The Third People's Hospital of Foshan, Guangdong, China. Electronic address: liangjiaquan@muc.edu.cn.
Förderung
- Foshan Municipal Science and Technology Bureau
Zitieren
APA
Liu, C., Ou, L., Tan, T., Deng, L., & Liang, J. (2026). Long-term efficacy and safety of paliperidone palmitate monthly injection and oral paliperidone extended-release tablets in schizophrenia, a randomized controlled trial. Acta Psychologica. https://doi.org/10.1016/j.actpsy.2025.106087
Vancouver
Liu C, Ou L, Tan T, Deng L, Liang J. Long-term efficacy and safety of paliperidone palmitate monthly injection and oral paliperidone extended-release tablets in schizophrenia, a randomized controlled trial. Acta Psychologica. 2026. doi:10.1016/j.actpsy.2025.106087
BibTeX
@article{Liu2026,
author = {Liu, Chunhui and Ou, Liqin and Tan, Tengjuan and Deng, Lingfeng and Liang, Jiaquan},
title = {Long-term efficacy and safety of paliperidone palmitate monthly injection and oral paliperidone extended-release tablets in schizophrenia, a randomized controlled trial},
journal = {Acta Psychologica},
year = {2026},
doi = {10.1016/j.actpsy.2025.106087}
}
EUVIMED